PixCell Medical Technologies Ltd.

Registration of the HemoScreen CBC Analyzer

PixCell Medical Technologies Ltd. a privately held company focused on developing its patented Cell Based Diagnostics technology for the Point of Care (POC), announced that it has raised $2 million following successful completion of CE mark registration of the HemoScreen Complete Blood Count (CBC) analyzer from its existing strategic investor.

This recent investment round will be used to establish PixCell’s European presence and expand its ongoing clinical efforts to introduce the HemoScreen technology to the market. HemoScreen CBC analyzer brings the laboratory to physicians' offices, to patient’s homes, isolated communities, ambulances and even to field units. Requiring only a minute blood sample and zero maintenance, it is also ideal for newborns hematology assessment.

PixCell's Viscoelastic Focusing and automated sample preparation proprietary technology, presents a breakthrough in live cell diagnostics, utilizing lab accurate and robust testers yet small sized, simple to operate and inexpensive.

“We are thrilled with our investors’ commitment to make HemoScreen POC technology available and accessible”, said PixCell Medical CEO Dr. Avishay Bransky. “PixCell’s goal is to make lab restricted tests more accessible, easy to use and affordable. With this new investment, PixCell is poised to expand its clinical efforts and further demonstrate how the HemoScreen technology can support diagnostics and treatment selection at the point of care.”

PixCell’s HemoScreen is a miniature, portable Point of Care Complete Blood Count (CBC) tester that employs disposable self-contained cartridges. The HemoScreen provides 20 standard CBC parameters including: RBC indices, WBC count, Hemoglobin, WBC 5-diff and platelets parameters. Tests results are obtained within 5 minutes using only 20µl of capillary/venous blood.

PixCell Medical plans to start a multi-center pilot study in Europe and Israel to evaluate the safety and performance of the HemoScreen system. Prior pre-clinical studies have successfully demonstrated its precision and accuracy in CBC analysis.